Diabetic foot ulcer. Diabetes mellitus due to underlying condition with diabetic neuropathic arthropathy
Conditions
Interventions
Intervention 1: Intervention group: In the first group, patients will be treated with vitamin D 50,000 units orally weekly for three weeks (conventional regimen).Tablets will be provided by Dana Phar
Sponsors
Oroumia University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Patients with vitamin D levels between 10-30 ng/dL Age over 18 years Diabetic foot ulcer grade 3 and 4 according to Wegener criteria Plasma calcium below 10 Platelet count above 100,000
Exclusion criteria
Exclusion criteria: Allergy to vitamin D products Known diseases associated with hypercalcemia Pregnancy and breastfeeding Patients treated with chemotherapy or radiotherapy drugs Taking drugs that interfere with wound healing, such as: corticosteroids, a minimum dose equivalent to 40 mg of prednisolone, mycophenolate, cyclosporine, tacrolimus, rituximab Patients with severe renal failure, GFR<30 ml/min Taking vitamin D supplements during the last month Received injectable antibiotics for diabetic foot ulcer during the last month before hospitalization Stenosis and severe clogging of vessels of the lower limbs based on vascular ultrasound Chronic alcohol consumption of more than 250 cc daily
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Erythrocyte Sedimentation (ESR). Timepoint: Before and three weeks after the intervention. Method of measurement: Biochemistry test.;C-reactive protein (CRP). Timepoint: Before and three weeks after the intervention. Method of measurement: Biochemistry test.;Fasting blood sugar (FBS). Timepoint: Before and three weeks after the intervention. Method of measurement: Biochemistry test.;Glomerular filtration rate (GFR). Timepoint: Before and three weeks after the intervention. Method of measurement: Based on the formula.;Creatinine. Timepoint: Before and three weeks after the intervention. Method of measurement: Biochemistry test.;Alanine transaminase (ALT). Timepoint: Before and three weeks after the intervention. Method of measurement: Biochemistry test.;Aspartate transferase (AST). Timepoint: Before and three weeks after the intervention. Method of measurement: Biochemistry test.;Alkaline phosphatase (ALP). Timepoint: Before and three weeks after the intervention. Method of measurement: Biochemistry test. | — |
Secondary
| Measure | Time frame |
|---|---|
| White blood count (WBC). Timepoint: Before and three weeks after the intervention. Method of measurement: Neobar slide (hemocytometer).;Mean platelet volume (MPV). Timepoint: Before and three weeks after the intervention. Method of measurement: Neobar slide (hemocytometer).;Platelet count. Timepoint: Before and three weeks after the intervention. Method of measurement: Neobar slide (hemocytometer).;Triglyceride (TG). Timepoint: Before and three weeks after the intervention. Method of measurement: Biochemistry test.;Cholesterol. Timepoint: Before and three weeks after the intervention. Method of measurement: Biochemistry test.;High-density lipoprotein (HDL). Timepoint: Before and three weeks after the intervention. Method of measurement: Biochemistry test.;Low-density lipoprotein (LDL). Timepoint: Before and three weeks after the intervention. Method of measurement: Biochemistry test.;Calcium. Timepoint: Before and three weeks after the intervention. Method of measurement: Biochemistry test.;Ferritin. Timepoint: Before and three weeks after the intervention. Method of measurement: Biochemistry test. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr. Laya Hooshmand
Oroumia University of Medical Sciences
Outcome results
None listed